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Abstract: Dihydrofolate reductase (DHFR) is the subject of intensive investigation since it 
appears to be the primary target enzyme for antifolate drugs. Fluorescence quenching 
experiments show that the ester bond-containing tea polyphenols (-)-epigallocatechin 
gallate (EGCG) and (-)-epicatechin gallate (ECG) are potent inhibitors of DHFR with 
dissociation constants (KD) of 0.9 and 1.8 μM, respectively, while polyphenols lacking the 
ester bound gallate moiety [e.g., (-)-epigallocatechin (EGC) and (-)-epicatechin (EC)] did 
not bind to this enzyme. To avoid stability and bioavailability problems associated with tea 
catechins we synthesized a methylated derivative of ECG (3-O-(3,4,5-trimethoxybenzoyl)-
(-)-epicatechin; TMECG), which effectively binds to DHFR (KD = 2.1 μM). In alkaline 
solution, TMECG generates a stable quinone methide product that strongly binds to the 
enzyme with a KD of 8.2 nM. Quercetin glucuronides also bind to DHFR but its effective 
binding was highly dependent of the sugar residue, with quercetin-3-xyloside being the 
stronger inhibitor of the enzyme with a KD of 0.6 μM. The finding that natural polyphenols 
are good inhibitors of human DHFR could explain the epidemiological data on their 
prophylactic effects for certain forms of cancer and open a possibility for the use of natural 
and synthetic polyphenols in cancer chemotherapy. 
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1. Introduction 
Recent studies have presented data that show a variety of biological activities of tea catechins, 
compounds which constitute about 15% (dry weight) of green tea [1,2]. Green tea catechins include:  
(-)-epigallocatechin gallate (EGCG), (-)-epigallocatechin (EGC), (-)-epicatechin gallate (ECG) and   
(-)-epicatechin (EC). EGCG is the most abundant (one 240 mL cup of brewed tea contains up to  
200 mg EGCG), and many health benefits, including antioxidant, antibiotic and antiviral activities, 
have been attributed to this compound [3–5]. Some authors consider EGCG alone to be the active 
anticancer component, while others suggest that other tea constituents also have antiproliferative or 
anticarcinogenic properties [6]. Green tea extracts have been shown in vitro to stimulate apoptosis of 
various cancer cell lines, including prostate, lymphoma, colon, and lung [1,6–8]. Moreover, EGCG 
was reported to inhibit tumour invasion and angiogenesis, processes that are essential for tumour 
growth and metastasis [6]. Despite great efforts during the last two decades to understand the 
anticarcinogenic activity of tea, the exact mechanism(s) of action are not well defined. Therefore, 
deciphering the molecular mechanism by which green tea or its polyphenols impart their 
antiproliferative effects could be important and may result in improved opportunities for the treatment 
of cancer. 
Dihydrofolate reductase (DHFR; 5,6,7,8-tetrahydrofolate: NADP
+ oxidoreductase, EC 1.5.1.3) 
catalyzes the reduction of 7,8-dihydrofolate (DHF) to 5,6,7,8-tetrahydrofolate (THF) in the presence of 
coenzyme NADPH as follows: DHF + NADPH + H
+ → THF + NADP
+. This enzyme is necessary for 
maintaining intracellular pools of THF and its derivatives which are essential cofactors in one-carbon 
metabolism. Coupled with thymidylate synthase [9], it is directly involved in thymidylate (dTMP) 
production through a de novo pathway. DHFR is therefore pivotal in providing purines and pyrimidine 
precursors for the biosynthesis of DNA, RNA and amino acids. In addition, it is the target enzyme [10] 
for antifolate drugs such as the antineoplastic drug methotrexate (MTX) and the antibacterial drug 
trimethoprim (TMP). Because of its biological and pharmacological importance, DHFR has been the 
subject of extensive structural and kinetic studies [11]. Based on the observation that classical (MTX) 
and non-classical (TMP or TQD) antifolate compounds possess similar chemical structures to some tea 
polyphenols [12] (Figures 1 and 2), we started to work on the hypothesis that tea catechins could 
inhibit DHFR activity. Suppression of DNA synthesis by tea catechins could explain many of the 
observed effects on cancer inhibition by these compounds. Recently, we have shown that ester bonded 
gallate catechins isolated from green tea, such as EGCG and ECG are potent inhibitors of DHFR 
activity  in vitro at concentrations found in the serum and tissues of green tea drinkers   
(0.1–1.0 μM) [12]. EGCG exhibited the kinetic characteristics of a slow-binding inhibitor of DHF 
reduction with bovine liver DHFR but of a classical, reversible, competitive inhibitor with chicken 
liver DHFR. Structural modelling showed that EGCG can bind to human DHFR in a similar 
orientation to that observed for a number of structurally characterized DHFR inhibitor complexes [12]. Int. J. Mol. Sci. 2009, 10                
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These results suggested that EGCG could act as an antifolate compound in the same way as MTX and 
TMP. In the present work, we have studied the binding of several natural and synthetic polyphenols to 
human DHFR and the structural requirements for such binding have been analyzed.  
Figure 1. Chemical structures of classical and non-classical antifolates compared with 
natural and synthetic polyphenols. Abbreviations: MTX, methotrexate; TQD,   
(R)-6-{[methyl-(3,4,5-trimethoxyphenyl)-amino]methyl}-5,6,7,8-tetrahydroquinazoline-
2,4-diamine; EC, (-)-epicatechin; EGC, (-)-epigallocatechin; ECG, (-)-epicatechin gallate; 
EGCG, (-)-epigallocatechin gallate; TMECG, 3-O-(3,4,5-trimethoxybenzoyl)-(-)-
epicatechin; Qglc, quercetin-3-β-D-glucoside; Qxyl, quercetin-3-D-xyloside; Qrha, 
quercetin-3-rhamnoside; Qgal, quercetin-3-D-galactoside. 
 
2. Results and Discussion 
2.1. Structural Requirements for the Binding of Tea Polyphenols to Human DHFR 
Green tea extracts containing significant amounts of tea catechins strongly inhibited the activity of 
bovine liver DHFR [13]. In order to detect which components of these extracts were responsible for 
such inhibition, human DHFR activity was assayed in the presence of EC, EGC, ECG or EGCG. The 
results showed that both ECG and EGCG were potent inhibitors of the human enzyme, while 
polyphenols lacking the ester bound gallate moiety (e.g., EGC and EC) did not inhibit this enzyme. 
The effective binding of ECG to free human DHFR was determined by following the decrease in 
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enzyme fluorescence that occurs after formation of the enzyme-inhibitor complex (Figure 3). When 
DHFR fluorescence is excited at 290 nm its emission spectrum shows a maximum at 340–350 nm. The 
binding of ECG quenches this fluorescence and the data showed that the dissociation constant of the 
enzyme-inhibitor complex was 1.78 ± 0.1 μM (Table 1).  
Figure 2. Structural comparison of natural (ECG) and synthetic (TMECG) polyphenols 
with classical (MTX) and non-classical (TQD) antifolates. 
 
Similar results were obtained for EGCG (Table 1); however, EC did not modify the emission 
spectra of human DHFR (Figure 3). These results indicate that the ester-bound gallate moiety is 
essential for the inhibition of this enzyme, as has been determined in the case of the bovine enzyme 
[12,13]. On searching the available ligand-bound human DHFR structures in the Protein Data Bank 
(PDB) [14], we identified a 1.8 Å structure (PDB accession code 1S3V [15]) containing a 
tetrahydroquinazoline antifolate ligand, TQD (Figures 1 and 2), as the best available structural match 
for ECG. Using the position of TQD as a guide, ECG was docked into this protein structure and the 
ECG-protein composite was then energy minimized using Insight II software (Figure 4). Comparison 
with a range of other DHFR structures containing folate or various inhibitors showed that most of the 
ECG lies within the consensual substrate/inhibitor envelope, with the exception of the non-ester 
trihydroxybenzene moiety. In order to accommodate this ring, the Leu-22 sidechain is required to 
adopt a different orientation; a precedent for this movement is provided by the crystal structure of a 
Tyr-22 mutant, which displays a similar geometry at this residue [16]. Although folate, TQD, MTX 
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and ECG are significantly different in terms of their structural formulae, they have similar 3D shapes, 
and this appears to be an important determinant of their binding to DHFR. There are also specific 
hydrogen bonding interactions, most notably that involving Glu-30. For folate and MTX, adjacent 
heterocyclic and amino nitrogens of the ligand form a pair of hydrogen bonds with the two oxygens of 
the Glu-30 sidechain (both O···N distances ≤ 2.8 Å). In contrast, ECG has only a single phenolic OH 
group available for hydrogen bonding to Glu-30 (O···O distance 2.7 Å).  
Figure 3. Titration fluorescence experiments for the binding of ECG and EC to human 
DHFR. In the left panel points are experimental (after correction for enzyme dilution) and 
the lines are best-fit theoretical curves. The enzyme concentration was 0.1 μM. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1. Dissociation constants for the binding of natural and synthetic polyphenols to 
human DHFR. 
Polyphenol  D K  (μM) 
Tea Catechins   
   EC  n.d.
A 
   EGC  n.d. 
   ECG  1.78 ± 0.10 
   EGCG  0.92 ± 0.12 
Synthetic Catechins   
   TMECG  2.1 ± 0.20 
   TMECG-QM      (8.2 ± 0.21) × 10
−3 
Flavonoids  
   Qglc  102 ± 9 
   Qxyl     0.59 ± 0.08 
   Qrha  17.2 ± 2.4 
   Qgal  22.8 ± 3.2 
An.d.: not determined. 
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Figure 4. Wall-eyed stereo view of ECG modeled into the folate-binding site of human 
DHFR. Carbon atoms of the ECG ligand and surrounding protein are colored green and 
grey respectively. Residue Phe-31, located behind the ECG, is unlabelled. Four different 
ligands from human and chicken DHFR crystal structures were used to define a binding 
envelope, shown in cyan; these were placed in a common orientation by superimposing 
backbone atoms from a common set of protein residues located around the ligands. 
Ligands from the following PDB structure files were used; 1DR1 (biopterin), 1S3V 
(TQD), 1S3W, and 1DLR. The figure was prepared using ViewerLite software.  
 
2.2. Binding of Synthetic Catechins to Human DHFR 
Despite the excellent anticancer properties of tea catechins, they have at least one great limitation: 
their poor bioavailability. The reduced availability of catechins is related with their low stability in 
neutral or slightly alkaline solutions and their poor ability to cross cellular membranes [17]. In an 
attempt to solve such bioavailability problems, we synthesized a 3,4,5-trimethoxybenzoyl analogue of 
ECG (3-O-(3,4,5-trimethoxybenzoyl)-(-)-epicatechin; TMECG; Figure 1), which showed high 
bioavailability in vitro and significant antiproliferative activity against different cancer cell lines [18]. 
This synthetic catechin also bound human DHFR with an effective dissociation constant of 
2.1 ± 0.2 μM (Figure 5; Table 1). Molecular modelling experiments showed that TMECG bound to 
human DHFR in a similar way to that described for ECG, with specific hydrogen bonding interactions, 
most notably involving Glu-30 (Figure 6). TMECG was highly stable at neutral pH but at alkaline pH 
rapidly evolves to an orange compound with an intense visible band at 470 nm. By analogy with the 
oxidation of quercetin in alkaline solution [19], the proposed structure for this compound is depicted 
in Figure 6 and was identified as a quinone methide (TMECG-QM) with an open structure. The 
affinity of human DHFR by TMECG-QM was assayed employing fluorescence quenching and the 
data showed a dissociation constant of 8.2 ± 0.11 nM (Figure 5; Table 1).  
 Int. J. Mol. Sci. 2009, 10                
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Figure 5. Titration fluorescence experiments for the binding of TMECG () and TMECG-
QM (z) to human DHFR. Points are experimental (after correction for enzyme dilution) 
and the lines are best-fit theoretical curves. The enzyme concentration was 0.1 μM. For 
comparison the data obtained for ECG (S) binding to human DHFR is included in   
the figure. 
 
 
 
 
 
Compared with other inhibitors of the enzyme, TMECG-QM showed intermediate affinity between 
MTX and catechins; thus, TMECG-QM bound more than two-order of magnitude more strongly than 
EGCG, ECG or TMECG but forty-times less than MTX (Table 1). Molecular modelling helped us to 
understand the high affinity of human DHFR for TMECG-QM. The open structure of the TMECG-
QM increases its molecular flexibility and adopts a different conformation in the active site of human 
DHFR (Figure 6).  
Figure 6. Molecular modelling for the binding of TMECG and TMECG-QM to human 
DHFR. The protein is depicted in ribbon representation and colored by secondary 
structures (i.e., helix, strand, and loop). The lower panel represents the proposed structure 
for TMECG-QM and the hydrogen-bonding network of TMECG-QM in human DHFR. 
Residues hydrogen bonded directly to TMECG-QM are depicted in red and the predicted 
distances in Å are showed. W represents a water molecule.  
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Figure 6. Cont. 
 
 
 
 
 
 
 
 
 
 
 
 
 
TMECG-QM maintained the hydrogen bond with Glu-30 side chain (O···O distance 1.99 Å), but 
three new interactions were detected. Thus, the other phenolic group of the ring A of TMECG-QH 
forms a hydrogen bond with Ile-7, whereas the other two hydrogen bonds were formed between two 
oxygens of the methoxy groups of ring D and Ser-59 and Ile-60 (Figure 6). This strong interaction 
between TMECG-QM and different residues of the protein explains the low dissociation constant for 
the inhibitor-protein complex. 
2.3. Binding of Natural Flavonoids to Human DHFR 
Flavonoids are naturally occurring polyphenolic compounds and
 have profound pharmacological 
properties, and a daily intake
 of flavonoids is associated with a lower risk of cancer [20]. They are 
most commonly known for their antioxidant activity; however, it is now known that the health benefits 
they provide against cancer and heart disease are the result of other mechanisms [20]. Between them 
quercetin (3,3',4',5,7-pentahydroxyflavone) is one of the most studied flavonoids [21]. Quercetin has 
been shown to have diverse biological activities,
 including antiproliferative and apoptotic effects [22], 
although the mechanisms are still obscure. Quercetin
 treatment caused cell cycle arrest either at the 
G1/S or G2/M
 transition, depending on cell type [22,23]. Moreover, quercetin-mediated
 apoptosis may 
be related to many factors such as stress proteins,
 disruption of microtubules, nuclear factor κB, Cox-2, 
p53, survivin,
 c-Jun NH2-terminal kinase, mitogen-activated protein kinase
 kinase-extracellular signal-
regulated kinase, Bcl-2 family proteins,
  heat shock proteins, DNA topoisomerase II, release of 
cytochrome
 c, and activation of caspases [22–24]. Quercetin has been reported
 to inhibit the growth of 
various human cancers, including leukemia,
  breast, esophagus, colon, prostate, nasopharyngeal, 
endometrial,
 and lung cancers [22–24]. Quercetin is
 one of the major dietary flavonoids particularly 
abundant in
  fruits and vegetables [25]. Analysis of plasma
  of volunteers fed with a quercetin-
supplemented diet shows that
 quercetin is mainly circulating as quercetin glucuronides [26]. Most of 
the biological studies for
 assessing the properties of quercetin are performed on quercetin
 (aglycone), 
and there is limited information available regarding
 the biological effects of quercetin glucuronides. 
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close to the in vivo situation.  
Figure 7. Titration fluorescence experiments for the binding of quercetin glucuronides to 
human DHFR. Points are experimental (after correction for enzyme dilution) and the lines 
are best-fit theoretical curves. The enzyme concentration was 0.1 μM. (●) Qglc (□) Qgal 
(▲) Qrha (○) Qxyl. 
 
 
 
 
 
 
 
 
 
 
The high structural similarity between quercetin glucuronides and ester bound gallate tea catechins 
(Figure 1) aim us to study the binding of these compounds to human DHFR. The four quercetin 
glucuronides used in this study have the same core structure (quercetin) but differ in the sugar moiety 
and in the number and spatial position of the OH groups linked to the sugar ring. The affinity of DHFR 
for these compounds will help us to identify the optimal conformation for the interaction and inhibition 
of human DHFR by these quercetin glucuronides. Figure 7 shows the fluorescence quenching of 
human DHFR by these flavonoids and Table 1 presents the calculated dissociation constants. Qxyl 
bound human DHFR much stronger than the other three quercetin glucuronides with a dissociation 
constant of 0.59 ± 0.08 μM. Qxyl and ECG show similar chemical structure (Figure 1) and similar 
dissociation constants for their binding to human DHFR (Table 1). However, the presence of a sugar 
ring in Qxyl instead a highly reactive phenolic gallate moiety in ECG could represent an advantage 
with respect to its stability and bioavailability, which could improve the effectiveness of Qxyl as an 
antifolate agent.  
2.4. Physiological and Therapeuthical Relevance 
In addition to the antioxidant activity of natural polyphenols, the finding that some of them are 
good inhibitors of human DHFR could explain the epidemiological data on the prophylactic effects of 
diets high in polyphenols for certain forms of cancer. A functional link between chronic inflammation 
and cancer has long been suspected. This link is of great interest in the context of this study because Int. J. Mol. Sci. 2009, 10                
           
 
5407
antifolates have shown remarkable anti-inflammatory activity [27]. Most solid tumours contain many 
non-malignant cells, including immune cells and blood-vessel cells, which are important in 
inflammation, although the crucial molecular pathways that permit communication between 
abnormally growing cancer cells and these inflammatory cells remain unknown. A mouse model of 
inflammation-associated cancer now implicates the gene transcription factor NF-κB and the 
inflammatory mediator known as TNF-α in cancer progression [28]. Several of the anti-inflammatory 
effects of MTX and other antifolates can be explained by the suppression of the activation of NF-κB, a 
multisubunit factor known to play a role in inflammation, immune modulation and cell proliferation. 
NF-κB is primarily composed of proteins with molecular masses of 50 kDa (p50) and 65 kDa (p65) 
and is retained in the cytoplasm by an inhibitory subunit, IκBα. NF-κB is activated by a wide variety 
of inflammatory stimuli, including TNF-α, which induces the phosphorylation-dependent degradation 
of IκBα, allowing active NF-κB to translocate to the nucleus and regulate gene expression. 
Suppression of the activation of NF-κB has been an effect widely observed in model cancer cells 
treated with tea catechins [29] of quercetin derived flavonoids [22–24]. These polyphenols are 
abundant in tea and other fruits and vegetables and the data presented here on its antifolate activity 
indicated that by regular consumption these polyphenols can combat chronic inflammation, and 
therefore, impede cancer formation. The data presented here indicate that natural and synthetic 
polyphenols may well be beneficial, not only in the prevention but also in the treatment of cancer. 
Antifolates are usually used as chemotherapeutic agents for certain types of cancer. Although 
antifolates such as MTX attack proliferating tissues selectively, they are also toxic to normal cells. 
Deleterious side effects are seen against tissues that proliferate as part of their normal function; such 
tissues include intestinal mucosa, hair cells, and components of the immune system. The “soft” 
character of the polyphenols studied here could be developed for use in the treatment of cancer with 
significantly reduced side effects compared to those of the DHFR inhibitors currently in use in 
chemotherapy such as methotrexate. Recently, we observed that normal human melanocytes were 
highly resistant to TMECG-induced apoptosis at concentrations of the drug which killed melanoma 
cells by apoptosis [30]. Thus, our conclusions highlight the potential of natural polyphenols and their 
synthetic derivatives for clinical application as anti-carcinogenic and antibiotic agents and in the 
treatment of inflammatory disorders. 
3. Experimental Section 
Highly purified tea polyphenols EGCG (>95%), ECG (>98%), EGC (>98%), and EC (>98%)   
were purchased from Sigma Chemical Co. (Madrid, Spain). Qgal, Qglc, Qrha and Qxyl were form  
Fluka (Madrid, Spain). TMECG was successfully synthesized (70% recovery) from catechin   
with the subsequent inversion of the stereochemistry at C-3 and by reaction of with   
3,4,5-trimethoxybenzoylchloride (Sigma) [18]. To synthesize TMECG-QM, a TMECG solution   
(0.5 mM) in phosphate buffered saline (PBS), pH 7.0, was alkalinize at pH 8.5 with NaOH. The 
reaction was followed spectrophotometrically at 470 nm and, after completion, the sample was 
neutralized by adding HCl. Recombinant human DHFR was purchased from Sigma and its 
concentration was determined by MTX titration of enzyme fluorescence [31]. Int. J. Mol. Sci. 2009, 10                
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The fluorescence of DHFR is reduced on binding of substrates and inhibitors, and this property may 
be used as a convenient method for determining both the enzyme concentration and the dissociation 
constants of enzyme-ligands complexes. Dissociation constants for the binding of polyphenols to free 
DHFR were determined by fluorescence titration in an automatic-scanning Perkin-Elmer LS50B 
spectrofluorimeter with 1.0 cm light path cells and equipped with a 150W xenon (XBO) light source. 
The formation of the binary complex between the enzyme and the ligand was followed by measuring 
the quenching of tryptophan fluorescence of the enzyme upon addition of microliter volumes of a 
concentrated stock solution of ligand. Fluorescence emission spectra were recorded when DHFR 
fluorescence was excited at 290 nm. All measurements were corrected for dilution and the data from 
the titration curves were fitted as described previously [32,33]. Titrations were performed in a buffer 
containing 2-(N-morpholino)ethanesulfonic acid (Mes, 0.025 M), sodium acetate (0.025 M), 
tris(hydroxymethyl)aminomethane (Tris 0.05 M), and NaCl (0.1 M), at pH 7.4.  
Molecular modeling was carried out using the Discover module of Insight II (Insight II, release 
2000.1, Accelrys Ltd. Cambridge, UK). Human DHFR X-ray crystal structure 1S3V [15] was retrieved 
from the protein data bank [14], and its TQD ligand was used as a template for positioning of the ECG 
ligand. The composite protein/ECG model was geometry optimized within Insight II using the 
consistent valence force field and steepest descent algorithm to a derivative of 1.0. The refined model 
was validated within InsightII using Prostat. 
4. Conclusions 
The results of this study demonstrate the binding capacity of natural and synthetic polyphenols to 
human DHFR. The results suggest that in vivo inhibition of DHFR by polyphenols could be of 
importance to explain the prophylactic and anticancer properties described for these natural 
compounds. This study also indicates that natural polyphenols could be used as guide compounds for 
development of new antifolates. 
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